anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Participants will be recruited informed and asked for participation in the study by health care professionals. If included in the study, and choosing the Safe Step exercise program as intervention, participants will be given a green prescription for exercise using the application Safe Step. After an introduction meeting in small groups and pre-assessments the participants will create an individual exercise programme containing ten balance and leg strengthening exercises in the application. During the four month intervention the participants will create weekly exercise plan, keep a digital exercise diary, and receive motivational feed-back within the system. The participants will be recommended to exercise at least three times per week and for at least 30 minutes at a time.
This invention relates to heterocyclic compounds, namely to octyl ester of 2-thiazolylamide of citraconic acid with analgesic effect. Purpose û revealing more active compounds. It is obtained by reaction of 2- thiazolylamide of citraconic acid with octanol. Output is 49 %. Temperature is + 96-98 DEGREE C. Structural formula is C16H24O3N2S. LD50=5220 mg/kg.
A severed nerve may be surgically rejoined and severed axons fused via sequential administrations of solutions. The solutions may include a priming solution comprising methylene blue in a Ca 2+ -free saline solution, a fusion solution comprising about 50% (w/w) PEG, and a sealing solution comprising Ca 2+ -containing saline. The PEG fusion solution may be applied in a nerve treatment device configured to isolate the injured segment of the nerve. The device may include a containment chamber for creating a fluid containment field around the anastomosis. The device may have slits, slots, and/or apertures in opposing endwalls of the device designed to receive the nerve. The device may have an open bath configuration or may include separable lower and upper bodies to create a closed bath configuration. The device may include one or more fluid ports in fluid communication with the containment chamber for introducing and/or removing fluid.
### Teratogenic Effects

There are no adequate and well-controlled studies on the use of doxycycline in pregnant women. The vast majority of reported experience with doxycycline during human pregnancy is short-term, first trimester exposure. There are no human data available to assess the effects of long-term therapy of doxycycline in pregnant women, such as that proposed for treatment of anthrax exposure. An expert review of published data on experiences with doxycycline use during pregnancy by TERIS – the Teratogen Information System – concluded that therapeutic doses during pregnancy are unlikely to pose a substantial teratogenic risk (the quantity and quality of data were assessed as limited to fair), but the data are insufficient to state that there is no risk. 1 A case-control study (18,515 mothers of infants with congenital anomalies and 32,804 mothers of infants with no congenital anomalies) shows a weak but marginally statistically significant association with total malformations and use of doxycycline anytime during pregnancy. Sixty-three (0.19%) of the controls and fifty-six (0.30%) of the cases were treated with doxycycline. This association was not seen when the analysis was confined to maternal treatment during the period of organogenesis (i.e., in the second and third months of gestation) with the exception of a marginal relationship with neural tube defect based on only two exposed cases. 2

A small prospective study of 81 pregnancies describes 43 pregnant women treated for 10 days with doxycycline during early first trimester. All mothers reported their exposed infants were normal at 1 year of age. 3

### Nonteratogenic Effects

(See WARNINGS.)
PURPOSE: To obtain a new human neurotensin receptor protein having a specific amino acid sequence, useful for e.g. screening human neurotensin receptor agonists or antagonists, thus to be used for e.g. developing preventive/therapeutic agents for depression, dementia, obnubilation, etc. CONSTITUTION: This new protein has an amino acid sequence including an amino acid sequence of the formula. This protein is used for e.g. screening human neurotensin receptor agonists or antagonists, being useful for the early development of preventive/therapeutic agents as agonists for Parkinson's disease, depression, dementia, hyperkinetic syndrome and obnubilation, and as antagonists for enteritis, pancreatltls, ulcer, stomach cancer, enterocarcinoma, insanity etc. This protein is obtained by making a cDNA library by using mRNAs extracted from human colon cancer culture cells, screening the library with a probe and then by manifesting the resultant human neurotensin receptor gene in host cells.
FIELD: agriculture. SUBSTANCE: polycarpic capacity of female cattle is stimulated by a hormonal preparation - Byelorussian follicle-stimulating hormone. The preparation is produced from hypophysis of pigs by ion-exchange chromatography and gel filtration. The use of said hormone during artificial insemination of cows raises polycarpic capacity of animals and birth of twins by 31.8%. EFFECT: higher reproduction of cattle. 1 tbl
Gabapentin is given orally with or without food.

If gabapentin dose is reduced, discontinued, or substituted with an alternative medication, this should be done gradually over a minimum of 1 week (a longer period may be needed at the discretion of the prescriber).

Postherpetic NeuralgiaIn adults with postherpetic neuralgia, gabapentin therapy may be initiated as a single 300-mg dose on Day 1, 600 mg/day on Day 2 (divided BID), and 900 mg/day on Day 3 (divided TID). The dose can subsequently be titrated up as needed for pain relief to a daily dose of 1800 mg (divided TID). In clinical studies, efficacy was demonstrated over a range of doses from 1800 mg/day to 3600 mg/day with comparable effects across the dose range. Additional benefit of using doses greater than 1800 mg/day was not demonstrated.

EpilepsyGabapentin is recommended for add-on therapy in patients 3 years of age and older. Effectiveness in pediatric patients below the age of 3 years has not been established.

Patients >12 years of age: The effective dose of gabapentin is 900 to 1800 mg/day and given in divided doses (three times a day) using 300 or 400 mg capsules. The starting dose is 300 mg three times a day. If necessary, the dose may be increased using 300 or 400 mg capsules three times a day up to 1800 mg/day. Dosages up to 2400 mg/day have been well tolerated in long-term clinical studies. Doses of 3600 mg/day have also been administered to a small number of patients for a relatively short duration, and have been well tolerated. The maximum time between doses in the TID schedule should not exceed 12 hours.
The invention discloses an animal model induced by combination of intraocular antigen immunization and endotoxin, and an establishment method thereof. The establishment method comprises following steps, an animal is immunized by eye uveal or retinal antigen, and Freund's complete adjuvant; and 7 to 10 days later, endotoxin is applied by plantar injection so as to induce experimental autoimmune uveitis (EAU) and retinitis of the animal. The eye uveal or retinal antigen is a protein or a polypeptide obtained by natural extraction, genetic engineering recombination and chemical synthesis. The retinal antigen is a protein or polypeptide antigen such as interphotoreceptor retinoid-binding protein and retinal soluble antigen of human or animal. The animal is a mouse or a rat. The endotoxin is a cell wall coating component of gram-negative bacterium such as escherichia coli, salmonella, shigella, and yersinia. The EAU mould of the invention is capable of simulating 'natural' pathogenesis environment of human preferably, and is beneficial for eliminating influences of pertussis toxin (PTX) on EAU. In addition, the model established by a C57BL/6 mouse is beneficial for applications of gene modification and gene defect technology in research of pathogenesis and mechanism of EAU.
The association between sleep and the immune-endocrine system is well recognized, but the nature of that relationship is not well understood. Sleep fragmentation induces a pro-inflammatory response in peripheral tissues and brain, but it also activates the hypothalamic-pituitary-adrenal (HPA) axis, releasing glucocorticoids (GCs) (cortisol in humans and corticosterone in mice). It is unclear whether this rapid release of glucocorticoids acts to potentiate or dampen the inflammatory response in the short term. The purpose of this study was to determine whether blocking or suppressing glucocorticoid activity will affect the inflammatory response from acute sleep fragmentation (ASF). Male C57BL/6J mice were injected i.p. with either 0.9% NaCl (vehicle 1), metyrapone (a glucocorticoid synthesis inhibitor, dissolved in vehicle 1), 2% ethanol in polyethylene glycol (vehicle 2), or mifepristone (a glucocorticoid receptor antagonist, dissolved in vehicle 2) 10 min before the start of ASF or no sleep fragmentation (NSF). After 24 h, samples were collected from brain (prefrontal cortex, hypothalamus, hippocampus) and periphery (liver, spleen, heart, and epididymal white adipose tissue (EWAT)). Proinflammatory gene expression (TNF-α and IL-1β) was measured, followed by gene expression analysis. Metyrapone treatment affected pro-inflammatory cytokine gene expression during ASF in some peripheral tissues, but not in the brain. More specifically, metyrapone treatment suppressed IL-1β expression in EWAT during ASF, which implies a pro-inflammatory effect of GCs. However, in cardiac tissue, metyrapone treatment increased TNF-α expression in ASF mice, suggesting an anti-inflammatory effect of GCs. Mifepristone treatment yielded more significant results than metyrapone, reducing TNF-α expression in liver (only NSF mice) and cardiac tissue during ASF, indicating a pro-inflammatory role. Conversely, in the spleen of ASF-mice, mifepristone increased pro-inflammatory cytokines (TNF-α and IL-1β), demonstrating an anti-inflammatory role. Furthermore, irrespective of sleep fragmentation, mifepristone increased pro-inflammatory cytokine gene expression in heart (IL-1β), pre-frontal cortex (IL-1β), and hypothalamus (IL-1β). The results provide mixed evidence for pro- and anti-inflammatory functions of corticosterone to regulate inflammatory responses to acute sleep loss.
A cosmetic product kit and method is provided for removing keratotic plugs from pores on various areas of the face. Included within the kit are at least two different types of strips each with differing geometry for placement along specific portions of a person's facial anatomy. For instance, there may be specific strips for the forehead, nose and chin/cheeks. These strips are flexible substrate sheets upon which an adhesive polymer is deposited. The method involves wetting the strip to tackify the polymer and activate the adhesivity. The strips are applied to the relevant area of the face, allowed to air dry and peeled away thereby removing the keratotic plugs from the pores.
The current study is designed as a multicenter, open-label, multiple-dose study in children and adolescent patients \>= 10 to \<= 17 years of age with schizophrenia, schizoaffective disorder, or schizophreniform disorder. The study includes 3 dosage groups (0.086, 0.129, and 0.171 mg/kg/day paliperidone ER), which will be studied in a sequential ascending design, so that the safety of the drug can be properly evaluated with a lower dosage before proceeding to the next higher dosage. The 3 dosages are approximately 6, 9, and 12 mg/day in adults. Within each dosage group, patients will be randomly assigned to 1 of 2 pharmacokinetic sampling schedules in a 1:1 ratio. For each dosage group, the study consists of a screening phase (for a maximum of 21 days); a 2-day, single-dose pharmacokinetic and tolerability evaluation phase; a 7-day multiple-dose phase, with evaluation of pharmacokinetics and tolerability; and an end-of-study visit. Following the completion of all patients in a given dosage group, the sponsor will evaluate the safety and tolerability of the treatment, in order to determine whether to proceed to the next higher or lower dosage level. The first group will start at 0.086 mg/kg/day. The hypothesis is that paliperidone ER will be well tolerated in children and adolescent patients with schizophrenia, schizoaffective disorder, or schizophreniform disorder, and will display the expected pharmacokinetic characteristics in this population. Paliperidone ER 0.086, 0.129, and 0.171 mg/kg/day, oral administration, single dose on Day 1 of study followed by once daily dosing on Days 3 to 9.
The invention relates to a preparation method, a detection method and application of a probe drug composition for determination of metabolic activity of cytochrome P450. The composition mainly comprises a preparation made with a specific probe with major isoforms of CYP450, i.e. CYP1A2, CYP2C9, CYP2C19, CYP2D6, CYP2E1 and CYP3A4, as an active component. Cocktail probe drug solution is prepared, the probe drug composition is injected into an animal or liver microsomes for in vitro co-incubation, and the concentration of each probe drug is determined to assess the metabolic activity of the CYP1A2, CYP2C9, CYP2C19, CYP2D6, CYP2E1 and CYP3A4. In the early stage of research and development of new drugs, the effects of the drugs on the activity of each isoform of the cytochrome P450 are screened in a high-throughput way, and the interactions of the drugs can be predicted. In the stage of clinical research, the testing can be performed with the probe drug composition in an in-vivo probe method, and the effects of the drugs on the in-vivo metabolic activity of different isoforms of the human liver CYP450 can be examined.
Paradoxical sleep deprivation (PSD) presents different effects on metabolism and neurological functions. In addition, over long duration, sleep restriction (SR) can promote permanent changes. The prostate is an endocrine-dependent organ with homeostatic regulation directly related to hormone levels. Our study proposed to demonstrate the experimental prostatic effects of PSD (96 h), PSD with recovery (PSR - 96/96 h), and sleep restriction (SR - 30 PSD cycles/recovery). PSD and SR promoted decrease in serum testosterone and significant increase in serum and intraprostatic corticosterone. In agreement, androgen receptors (AR) were less expressed and glucocorticoid receptors (GR) were enhanced in PSR and SR. Thus, the prostate, especially under SR, demonstrates a castration-like effect due to loss of responsiveness and sensitization by androgens. SR triggered an important inflammatory response through enhancement of serum and intraprostatic pro- (IL-1α, IL-6, TNF-α) and anti-inflammatory (IL-10) cytokines. Furthermore, the respective receptors of anti-inflammatory cytokines (IL-1RI and TNF-R) were highly expressed in the prostatic epithelium and stroma. PSR can partially restore prostate homeostasis, as it restores testosterone and the prostate proliferation index, in addition to promoting balance in the inflammatory response that is considered protective. PSD and SR are key factors in the endocrine axis that coordinate prostatic homeostasis, and significant changes in these factors have consequences on prostate functionality.
This is a biobanking project for individuals with mutations in MECP2, CDKL5, and FOXG1 to understand the interplay of mutations in these individuals and the resultant phenotypic expression; for example, individuals with mutations in MECP2 but not meeting diagnostic criteria for Rett syndrome or individuals with mutations in CDKL5 or FOXG1 who may or may not meet diagnostic criteria for atypical Rett syndrome. No interventions are anticipated.
Total calories will be set according to Look AHEAD intervention, and carbohydrate consumption restriction will be set based on recommendations from American Diabetic Association, National Kidney Foundation, and other evidence-based resources. Participants in this group will be asked to consume a low-carb/ketogenic diet. Specially, participants will receive a carbohydrate, protein, and fat intake goal based on 1.5 : 1 ratio (1.5 grams of fat to 1 gram of carbohydrate and protein combined). Daily macronutrient and calorie consumption will be individualized for each participant using ideal body weight as inferred from wrist circumference and activity level. Carbohydrate consumption will be less than 10% (20\~50 g), protein 10-20% (1.0\~1.2g/kg ideal body weight), and fat 70-80% of total daily energy, respectively. Nutritional ketosis will be reached by consuming such diet (0.5 mmol/L).
FIELD: experimental biology. SUBSTANCE: method for administration of biological agents into eggs involves injecting agents in a particle-like carrier into the air-chambers of the eggs. It is expedient to position the eggs vertically with their air-chambers directed upward to facilitate migration of the carrier between the external and internal membranes. The carrier releases the biological agent into the surrounding liquid and blood vessels. The carrier will keep releasing the agent in the hatched chick as well. The composition of polyester microparticles contains biologically active polypeptide agents. The composition consists of biologically compatible and decomposable microparticles having a polyester matrix and approximately 5-25% (by weight) of active water-soluble polypeptide dispersed in the whole matrix. The polypeptide is chosen from a group comprising a factor that releases the growth-promoting hormone, synthetic substances analogous to the factor, and its pharmacologically active fragments. The method for production of the composition involves dissolving polyester in some organic solvent, suspending the biologically active agent in the polyester solution, emulsification of the suspension in water medium where the agent is not soluble, and evaporation of the solvent from the emulsion. The microparticles are suspended in some appropriate liquid before injection. EFFECT: more effective method.
The invention discloses an antibacterial peptide fusion protein and a preparation method and application thereof, and relates to the technical field of biological pharmaceutical engineering. The amino acid sequence of the antibacterial peptide fusion protein is shown as SEQ ID NO. 7. The invention designs an antibacterial peptide fusion protein Cb-SOD-Cb by fusing two ends of human zinc-copper superoxide dismutase with antibacterial peptide cecropin B through a flexible peptide chain. The antibacterial peptide fusion protein has antioxidant activity and antibacterial activity, and can be used for preparing antibacterial drugs and skin care products. The invention adopts the inclusion body to express the antibacterial peptide fusion protein Cb-SOD-Cb in host cells, avoids the damage of recombinant protein generated by soluble expression to the host, and adopts the inclusion body cleaning, impurity removal and renaturation technology to prepare the recombinant protein with antibacterial activity and oxidation resistance.
A system includes memory hardware storing processor-executable instructions, a persona, and a data structure associated with the persona. Processor hardware executes the processor-executable instructions. The instructions include generating a graphical user interface and, in response to a first condition, inputting a first set of explanatory variables to a first trained machine learning model to generate a first metric and transforming the graphical user interface according to the persona and the first metric. The instructions include, in response to a second condition, inputting a second set of explanatory variables to a second trained machine learning model to generate a second metric and transforming the graphical user interface according to the persona and the second metric. The first trained machine learning model is different from the second trained machine learning model. The instructions include automatically approving a first prior authorization prescription in response to the first metric reaching a threshold value.
Disclosed are novel pharmaceutical, animal feed compositions and methods of treating non-human animals comprising at least one component selected from the extract(s), fraction(s), active compound(s) and phytochemical(s), or mixtures thereof, derived from non-woody plants of the genus  Hesperaloe . Animal feed compositions may comprise a basal animal feed and water soluble solids extracted from  Hesperaloe  and comprising at least one saponin. The water soluble solids may comprise from about 5 to about 30 wt % saponin. The compositions of the present invention can be used for the treatment of non-human animals, such as poultry and more particularly for preventing and treating coccidiosis. An embodiment provides an immunological composition useful for inducing the production of antibodies to an antigen in a non-human animal comprising an antigen, preferably a coccidia, and a saponin composition extracted from  Hesperaloe . The saponins extracted from  Hesperaloe  biomass may comprise 25(27)-dehydrofucreastatin, 5(6),25(27)-disdehydroyuccaloiside C, 5(6)-disdehydroyuccaloiside C, furcreastatin and yuccaloiside C.
FIELD: medicine. SUBSTANCE: invention relates to immunomodulating agent that can be used for treatment of different diseases accompanying with disorders of immune system immunomodulating activity. Agent has phospholipoglycoproteoselenium complex including low-molecular selenium compound, protein component obtained by extraction with organic solvents and the following drying the substance and dissolving in alcohol, organic carbohydrates, phospholipids, calcium, magnesium and aluminium cations as inorganic ions, hydrosulfite ions and hydroorthosilicate anions as liquid solutions. Mixture of these substances is placed and kept in electromagnetic sinusoidal high-frequency field at 20-30 MHz. One ml of immunomodulating agent has 30-40 mg of substance and 6-12 mcg of selenium in the mole ratio of phospholipid to glycoside and proteoselenium = 1:1:1 and phospholipoglycoproteoselenium complex to inorganic ionized structures = (1:2)-(1:7). Invention relates to method of immunomodulation also. Invention provides the systemic curative effect based on activation of cellular and humoral immune processes, among them the recognition of foreign antigen as the main mechanism of immunomodulating activity. EFFECT: enhanced effectiveness of agent, improved method of immunomodulation. 19 cl, 8 ex
A system for managing prescriptions via a blockchain is provided. The system records in the blockchain a prescription transaction that identifies a prescription that has been written for a patient. The system then records in the blockchain a submission selection transaction with code for controlling selection of a pharmacy to dispense the prescription. For pharmacies that provide a submission for dispensing the prescription, the system records in the blockchain a submission transaction with submission information relating to dispensing of the prescription by the pharmacy. When a pharmacy is selected to dispense the prescription, the system records in the blockchain a selected submission transaction indicating the pharmacy selected to dispense the prescription. When the prescription is dispensed, the system records in the blockchain a dispense transaction indicating that the selected pharmacy has dispensed the prescription.